

**Contacts Media**

Amsterdam +31 20 721 4133  
Dublin +353 87 361 2380  
Milan +39 02 72 42 62 12  
Paris +33 1 70 48 24 45

Brussels +32 2 620 15 50  
Lisbon +351 210 600 614  
Oslo +47 41 69 59 10

**Contact Investor Relations**

+33 1 70 48 24 27

## BenevolentAI lists on Euronext Amsterdam

- **Listed following business combination with Odyssey Acquisition S.A.**
- **3<sup>rd</sup> SPAC business combination on Euronext markets in 2022**


**Benevolent<sup>AI</sup>**

**Amsterdam – 25 April 2022** – Euronext today congratulates BenevolentAI, a leading, clinical-stage, AI-enabled drug discovery company, on its listing on Euronext Amsterdam (ticker code: BAI). The company has listed following the completion of its successful business combination with Odyssey Acquisition S.A., a special purpose acquisition company that listed on Euronext markets on 22 April 2022.

BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company with proven track-record of scientifically validated discoveries. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

The completion of the business combination with Odyssey, and the proceeds from the transaction, will further enable BenevolentAI to accelerate the development of its clinical pipeline and continue investing in its technology platform.

Joanna Shields, Chief Executive Officer of BenevolentAI, said: *"BenevolentAI stands out in the AI-enabled drug discovery sector. Our AI platform is fully operational, scientifically validated, and supports an in-house pipeline of over 20 platform-generated drug programmes and successful commercial collaborations. Through this listing, we are well-placed to strengthen our leadership position, ensuring we can continue to accelerate investment in the development of our pipeline and technology."*



**Caption:** Joanna Shields, CEO of BenevolentAI, and her team sounded the Gong this morning to celebrate the listing of the company on the Euronext Amsterdam. They were welcomed by Simone Huis in 't Veld (CEO Euronext Amsterdam) and René van Vlerken (Head of Listing Euronext Amsterdam).

**CONTACTS MEDIA – [mediateam@euronext.com](mailto:mediateam@euronext.com)**

Marianne Aalders (Amsterdam)

+31 20 721 41 33

[maalders@euronext.com](mailto:maalders@euronext.com)

**About BenevolentAI**

BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track-record of scientifically validated discoveries. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

**About Euronext**

Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €6.6 trillion in market capitalisation as of end March 2022, it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe's leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs. For the latest news, go to [euronext.com](http://euronext.com) or follow us on Twitter ([twitter.com/euronext](https://twitter.com/euronext)) and LinkedIn ([linkedin.com/euronext](https://linkedin.com/euronext)).



#### Disclaimer

This press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided "as is", without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at [www.euronext.com/terms-use](http://www.euronext.com/terms-use).

© 2022, Euronext N.V. - All rights reserved.

The Euronext Group processes your personal data in order to provide you with information about Euronext (the "Purpose"). With regard to the processing of this personal data, Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation, "GDPR"), and any applicable national laws, rules and regulations implementing the GDPR, as provided in its privacy statement available at: [www.euronext.com/privacy-policy](http://www.euronext.com/privacy-policy). In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights, please refer to: [www.euronext.com/data\\_subjects\\_rights\\_request\\_information](http://www.euronext.com/data_subjects_rights_request_information). To make a request regarding the processing of your data or to unsubscribe from this press release service, please use our data subject request form at [connect2.euronext.com/form/data-subjects-rights-request](http://connect2.euronext.com/form/data-subjects-rights-request) or email our Data Protection Officer at [dpo@euronext.com](mailto:dpo@euronext.com).

